Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

intervet international bv - febendatsoli - matolääkkeet , bentsimidatsoleja ja niihin liittyvät aineet, fenbendazole - pigs; chicken - hoito ja valvonta ruoansulatuskanavan sukkulamadot sikojen tartunnan kanssa:ascaris suum (aikuiset, suolistossa ja vaeltavien toukkien vaiheissa);oesophagostomum spp. (aikuisten vaiheet) trichuris suis (aikuiset vaiheissa). hoitoon ruoansulatuskanavan sukkulamadot kanojen tartunnan kanssa:ascaridia galli (l5 ja aikuiset vaiheissa);heterakis gallinarum (l5 ja aikuiset vaiheissa);capillaria spp. (l5 ja aikuisten vaiheissa).

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

roche registration gmbh - alectinib-hydrokloridia - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - alecensa monoterapiana on tarkoitettu ensilinjan hoito aikuispotilailla, anaplastinen lymfooma kinaasi (alk)-positiivinen pitkälle edennyt ei-pienisoluinen keuhkosyöpä (nsclc). alecensa monoterapiana on tarkoitettu aikuisille potilaille, joilla on alk‑positiivinen, edennyt ei-pienisoluinen keuhkosyöpä aiemmin käsitelty crizotinib.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karsinooma, ei-pienisoluinen keuhko - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - glucose monohydrate - infuusioneste, liuos - 300 mg/ml - hiilihydraatit

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - glucose monohydrate - infuusioneste, liuos - 100 mg/ml - hiilihydraatit

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - glucose monohydrate - infuusioneste, liuos - 200 mg/ml - hiilihydraatit

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - aspartic acid, glutamic acid, alanine, arginine, calcium chloride dihydrate, glucose monohydrate, aminoacetic acid, histidine, isoleucine, potassium dihydrogen phosphate , potassium hydroxide, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophane, valine, sodium acetate trihydrate, sodium hydroxide, magnesium acetate tetrahydrate - infuusioneste, liuos - yhdistelmävalmisteet

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - aspartic acid, glutamic acid, alanine, arginine, calcium chloride dihydrate, glucose monohydrate, aminoacetic acid, histidine, isoleucine, potassium hydroxide, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophane, valine, sodium acetate trihydrate, sodium dihydrogen phosphate dihydrate, sodium hydroxide, magnesium acetate tetrahydrate - infuusioneste, liuos - yhdistelmävalmisteet

Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

csl behring gmbh - albumin, human - infuusioneste, liuos - 50 g/l - albumiini